Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tuuli Ranki

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Cancer Research|July 18, 2008
Tissue-specific promoters active in CD44+CD24-/low breast cancer cellsGerd J Bauerschmitz, Tuuli Ranki, Lotta Kangasniemi, et al.
Molecular Therapy Oncolytics|March 15, 2021
Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platformErkko Ylösmäki, Leena Ylösmäki, Manlio Fusciello, et al.
Cancer Research|February 29, 2020
Exploiting Preexisting Immunity to Enhance Oncolytic Cancer ImmunotherapySiri Tähtinen, Sara Feola, Cristian Capasso, et al.
Cancer Research|February 11, 2012
Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patientsSari Pesonen, Iulia Diaconu, Lotta Kangasniemi, et al.
Oncoimmunology|May 6, 2015
Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8<sup>+</sup> T-cell response, prominent infiltration of CD8<sup>+</sup> lymphocytes and Th1 type polarizationTuuli Ranki, Timo Joensuu, Elke Jäger, et al.
Journal for Immunotherapy of Cancer|March 17, 2016
Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markersTuuli Ranki, Sari Pesonen, Akseli Hemminki, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 29, 2010
Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSFAnniina Koski, Lotta Kangasniemi, Sophie Escutenaire, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Cancer Research|July 18, 2008
Tissue-specific promoters active in CD44+CD24-/low breast cancer cellsGerd J Bauerschmitz, Tuuli Ranki, Lotta Kangasniemi, et al.
Molecular Therapy Oncolytics|March 15, 2021
Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platformErkko Ylösmäki, Leena Ylösmäki, Manlio Fusciello, et al.
Cancer Research|February 29, 2020
Exploiting Preexisting Immunity to Enhance Oncolytic Cancer ImmunotherapySiri Tähtinen, Sara Feola, Cristian Capasso, et al.
Cancer Research|February 11, 2012
Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patientsSari Pesonen, Iulia Diaconu, Lotta Kangasniemi, et al.
Oncoimmunology|May 6, 2015
Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8<sup>+</sup> T-cell response, prominent infiltration of CD8<sup>+</sup> lymphocytes and Th1 type polarizationTuuli Ranki, Timo Joensuu, Elke Jäger, et al.
Journal for Immunotherapy of Cancer|March 17, 2016
Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markersTuuli Ranki, Sari Pesonen, Akseli Hemminki, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 29, 2010
Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSFAnniina Koski, Lotta Kangasniemi, Sophie Escutenaire, et al.
Pageof 2